A Phase I, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Abacavir/Dolutegravir/Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Dec 2015
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 18 Dec 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 08 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 02 Oct 2015 Planned initiation date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.